ISRA240719P37000
- 1.90
- 0.000.00%
VanEck Vectors Israel ETF Newsroom
Is the market becoming impatient? More and more people are discussing the fact that AI burns so much money but earns so little.
So far, AI technology has produced almost no economic benefits. Faced with the huge gap between burning and earning money with AI, the market's patience for technology stocks is gradually disappearing.
The AI wave has driven the amount of risk investment in the USA to a new high in nearly two years, while the exit activity has continued to be sluggish.
In the second quarter of 2024, the amount of venture capital in the USA reached $55.6 billion, a 47% increase compared to the previous period and also the highest in the past two years. However, the continued slump in exit activities also poses challenges to the sustainability of VC financing and subsequent investments.
Teva Focus of FTC Investigation Over Inhaler Patents
AI to Help Spur 15% Additional Gain in Tech Stocks in Second-half: Wedbush
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei
Amdocs Goes Ex Dividend Tomorrow
Gain Rotation Out of Semis Is Feeding Into Other Parts of the Market - Argus
Guggenheim Reiterates Buy on CyberArk Software, Maintains $300 Price Target
Guggenheim analyst Raymond McDonough reiterates CyberArk Software (NASDAQ:CYBR) with a Buy and maintains $300 price target.
Teva Expects No Impact From Israel Tax Authority Agreement On Its 2024 Financial Outlook, Which It Reaffirms
Teva Expects No Impact From Israel Tax Authority Agreement On Its 2024 Financial Outlook, Which It Reaffirms
Top 3 Tech Stocks Which Could Rescue Your Portfolio In June
The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.This launch adds to Teva's continued commitment to its complex generic m
Cantor Fitzgerald Reiterates Overweight on CyberArk Software, Maintains $300 Price Target
Cantor Fitzgerald analyst Yi Fu Lee reiterates CyberArk Software (NASDAQ:CYBR) with a Overweight and maintains $300 price target.
Rubrik to Benefit the Most From CDK Global Cyberattack: Cantor Fitzgerald
Reported Wednesday, CyberArk Selected By India's IIFL Group To Reduce Cyber Risks And Streamline Compliance
Reported Wednesday, CyberArk Selected By India's IIFL Group To Reduce Cyber Risks And Streamline Compliance
Amdocs Joins Hands With Google Cloud for Better Data Insights
JMP Securities Reiterates Market Outperform on CyberArk Software, Maintains $310 Price Target
JMP Securities analyst Trevor Walsh reiterates CyberArk Software (NASDAQ:CYBR) with a Market Outperform and maintains $310 price target.
CyberArk Software Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 22.91% JMP Securities $310 → $310 Reiterates Market Outperform → Market Outperform 06/04/2024 1
U.S. Drug Shortages Worsen to Reach a Decade High: Report